Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
Rhea-AI Summary
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on April 20, 2026 at 8:00 am ET / 5:00 am PT to review 52-week topline results from the 16-week extension treatment period of the Phase 2b REZOLVE-AA study of rezpegaldesleukin for severe-to-very-severe alopecia areata.
The company will issue a morning press release, present slides during the webcast, and post the materials and a replay on its investor events page for at least 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
On the day this news was published, NKTR gained 18.25%, reflecting a significant positive market reaction. Argus tracked a peak move of +22.7% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $483M to the company's valuation, bringing the market cap to $3.13B at that time. Trading volume was very high at 4.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NKTR is up 1.04% while peers show mixed moves: SANA -1.12%, PRAX +4.98%, QURE +3.11%, ABUS +0.85%, SYRE +3.83%, suggesting a stock-specific setup into the data-focused call.
Previous Conferences,clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Clinical call announced | Neutral | +51.1% | Scheduled call for 36-week REZOLVE-AD Phase 2b topline results. |
| Dec 15 | Clinical call announced | Neutral | -7.8% | Planned call for 36-week induction REZOLVE-AA Phase 2b topline data. |
Announcements of conference calls for rezpegaldesleukin topline data have previously produced large, sometimes opposite, price moves, indicating sensitive expectations around clinical readouts.
Recent history for Nektar centers on rezpegaldesleukin clinical progress and investor communication. Prior same-tag events on Dec 15, 2025 and Feb 9, 2026 also announced conference calls to discuss Phase 2b topline data in alopecia areata and atopic dermatitis, with subsequent ‑7.77% and +51.07% moves, respectively. Today’s announcement of 52‑week topline REZOLVE‑AA data continues this pattern of milestone readouts for the program.
Historical Comparison
Past conference-call announcements for rezpegaldesleukin topline data moved NKTR an average of 21.65%, showing these updates have been major trading catalysts.
The sequence of calls reflects ongoing Phase 2b development for rezpegaldesleukin in atopic dermatitis and alopecia areata, moving from 36-week induction and maintenance data toward longer-term 52-week outcomes.
Market Pulse Summary
The stock surged +18.3% in the session following this news. A strong positive reaction aligns with how prior rezpegaldesleukin conference-call announcements have acted as catalysts, with average same-tag moves of 21.65%. However, history also shows opposing reactions to similar headlines, underscoring event-risk if 52-week REZOLVE-AA data underwhelms expectations. Elevated insider net selling and prior financing activity from regulatory filings may add to investor focus on how durable any strength proves.
Key Terms
phase 2b medical
clinical trial medical
regulatory T-cell medical
treg medical
alopecia areata medical
AI-generated analysis. Not financial advice.
Conference Call
The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.
The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in
For Investors:
Vivian Wu
628-895-0661
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026-302746623.html
SOURCE Nektar Therapeutics